Fortress Biotech (FBIO) Cut to Sell at ValuEngine

Fortress Biotech (NASDAQ:FBIO) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

A number of other research analysts also recently issued reports on FBIO. HC Wainwright set a $11.00 price objective on shares of Fortress Biotech and gave the company a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research raised shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $11.00.

Shares of Fortress Biotech (NASDAQ:FBIO) traded up $0.16 on Friday, hitting $4.01. 128,432 shares of the stock were exchanged, compared to its average volume of 72,443. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.69 and a quick ratio of 2.69. Fortress Biotech has a 1 year low of $1.88 and a 1 year high of $5.13.

Fortress Biotech (NASDAQ:FBIO) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.24). The firm had revenue of $46.89 million during the quarter, compared to analysts’ expectations of $50.75 million. Fortress Biotech had a negative return on equity of 61.43% and a negative net margin of 65.80%. The firm’s revenue for the quarter was up 4709.2% compared to the same quarter last year. equities research analysts expect that Fortress Biotech will post -1.61 earnings per share for the current year.

In other Fortress Biotech news, CEO Lindsay A. Md Rosenwald bought 40,000 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were purchased at an average price of $25.00 per share, for a total transaction of $1,000,000.00. Following the acquisition, the chief executive officer now owns 40,000 shares in the company, valued at approximately $1,000,000. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders own 33.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Rhumbline Advisers boosted its holdings in shares of Fortress Biotech by 2.8% during the 2nd quarter. Rhumbline Advisers now owns 38,846 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 1,075 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in Fortress Biotech by 3.3% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 59,224 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 1,913 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Fortress Biotech by 4.9% in the 1st quarter. Bank of New York Mellon Corp now owns 110,061 shares of the biopharmaceutical company’s stock worth $408,000 after purchasing an additional 5,170 shares in the last quarter. Northern Trust Corp boosted its stake in Fortress Biotech by 2.1% in the 2nd quarter. Northern Trust Corp now owns 386,435 shares of the biopharmaceutical company’s stock worth $1,836,000 after purchasing an additional 7,858 shares in the last quarter. Finally, National Asset Management Inc. boosted its stake in Fortress Biotech by 38.4% in the 2nd quarter. National Asset Management Inc. now owns 28,850 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 8,000 shares in the last quarter. Hedge funds and other institutional investors own 12.05% of the company’s stock.

WARNING: “Fortress Biotech (FBIO) Cut to Sell at ValuEngine” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/03/fortress-biotech-fbio-cut-to-sell-at-valuengine.html.

Fortress Biotech Company Profile

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Fortress Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply